hVIVO PLC (AIM:HVO) chief executive Yamin ‘Mo’ Khan takes Proactive's Stephen Gunnion through the company’s unaudited trading update for 2025, which revealed a strong performance amid industry-wide challenges.
hVIVO expects to report revenue of approximately £46.7 million for full-year 2025, in line with previous guidance, and anticipates EBITDA margins ahead of expectations, reversing a previously forecasted loss. Khan credited a stronger-than-expected Q4, early structural changes, and cancellation fees that carried high margins as key contributors to this outcome.
He also highlighted hVIVO’s strategic acquisitions of Cryostore in the UK and German CRO CRS. These deals filled a key gap in hVIVO’s service offerings, enabling the company to become a full-service, early-phase drug development provider across multiple therapeutic areas including cardiometabolic, respiratory and immunology.
“We are no longer a one-trick pony,” Khan said, referencing the diversification of services beyond infectious diseases and human challenge trials. He added that the company has restructured into four service pillars: clinical trials, human challenge trials, consulting, and lab services.
Discussing macroeconomic challenges in 2025, Khan acknowledged the headwinds but expressed optimism for 2026, supported by increased biotech funding and M&A activity. He pointed to the acquisition of hVIVO client Cidara by Merck as a strong signal of sector confidence.
hVIVO’s sales pipeline has broadened, with more varied opportunities and greater conversion rates into contracts. The company also aims to grow its presence in key therapeutic areas like cardiometabolic diseases and respiratory conditions, supported by a strong multinational infrastructure.
Visit Proactive’s YouTube channel for more videos, and don’t forget to give this video a like, subscribe to the channel, and enable notifications for future content.
#hVIVO #BiotechNews #CRO #ClinicalTrials #Cardiometabolic #Immunology #RespiratoryHealth #LifeSciences #PharmaNews #InvestingInBiotech #DrugDevelopment #EBITDA #RevenueGrowth #MergersAndAcquisitions #YaminKhan
